Picture1.png
Autolus Therapeutics receives Medicines and Healthcare products Regulatory Agency (MHRA) certification for Nucleus commercial manufacturing site
March 12, 2024 07:00 ET | Autolus Therapeutics plc
Autolus Therapeutics receives Medicines and Healthcare products Regulatory Agency (MHRA) certification for Nucleus commercial manufacturing site
Rentschler Biopharma logo from PR.jpg
Rentschler Biopharma’s ATMP facility in Stevenage, UK, receives MHRA approval
September 13, 2023 03:00 ET | Rentschler Biopharma SE
UK site now set for clinical production of adeno-associated virus (AAV) vectors for gene therapyHighly experienced team ready to support ATMP innovators at all stagesOffering comprehensive range of...
ADvantage logo.png
MHRA Grants ADvantage Therapeutics Innovative Licensing and Access Pathway (ILAP) Designation for Novel Lead Product AD04™ for Phase 2b Trial in Alzheimer’s Disease
April 05, 2023 08:35 ET | Advantage Therapeutics Inc.
MIAMI, April 05, 2023 (GLOBE NEWSWIRE) -- ADvantage Therapeutics, Inc. (“ADvantage” or “the Company”), which is developing therapies to treat neurodegenerative conditions with a central focus on...
Obseva Logo highresolution.jpg
ObsEva Announces UK MHRA Marketing Authorization for Yselty® (linzagolix), an Oral GnRH Antagonist, for the Treatment of Uterine Fibroids
June 28, 2022 16:01 ET | ObsEva SA
  -Yselty® (linzagolix) is the first and only approved GnRH antagonist to provide flexible dosing options with and without hormonal add-back therapy- -Theramex to commercialize Yselty®; ObsEva to...
NeuroSigma.png
NeuroSigma Announces King’s College London Team Receives MHRA Approval to Commence Largest Clinical Trial of eTNS for Pediatric ADHD to Date
April 07, 2022 11:00 ET | NeuroSigma, Inc.
Double-blind randomized controlled trial of eTNS for pediatric ADHD will enroll up to 150 participants at two sites in London and Southampton NeuroSigma’s Monarch eTNS System and electric patches to...
IN3BIO is a UK-based biotechnology company dedicated to developing new therapeutics that can provide cancer patients with new and effective treatments
MHRA Approves Phase I/II Clinical Trial of IN3BIO Vaccine to Improve Outcomes for Colorectal Cancer Patients
March 09, 2022 10:08 ET | IN3BIO
LONDON, March 09, 2022 (GLOBE NEWSWIRE) -- IN3BIO Research Limited, a leader in developing cancer treatments that, based upon clinical data, show significant promise and appear to be more tolerable...
Pfizer and BioNTech
Pfizer and BioNTech Achieve First Authorization in the World for a Vaccine to Combat COVID-19
December 02, 2020 02:05 ET | BioNTech SE
U.K. regulator, MHRA, authorizes supply of COVID-19 mRNA vaccine for emergency supply under Regulation 174; Companies are ready to deliver the first doses to the U.K. immediatelyFirst authorization...
Pfizer und BioNTech
Pfizer und BioNTech erhalten weltweit erste Zulassung für COVID-19-Impfstoff
December 02, 2020 02:05 ET | BioNTech SE
Die britische Regulierungsbehörde MHRA genehmigt die Lieferung von COVID-19-Impfstoff zur Notfallversorgung (gemäß Verordnung 174); erste Lieferungen werden innerhalb weniger Tage im Vereinigten...
Celixir provides update on ongoing clinical programme with lead therapeutic candidate CLXR-001
July 06, 2020 09:25 ET | CELIXIR Plc
Celixir provides update on ongoing clinical programme with lead therapeutic candidate CLXR-001 First patient successfully dosed in cardiomyopathy study Stratford-upon-Avon, UK: July, 6 2019...
ORION Logo Pantone(750x266).png
Orion Biotechnology Completes Scientific Advice Meeting with MHRA
October 31, 2018 11:19 ET | Orion Biotechnology Canada Ltd
OTTAWA, Oct. 31, 2018 (GLOBE NEWSWIRE) -- Orion Biotechnology Canada Ltd., a developer of novel medical treatments, announced today the completion of a scientific advice meeting with the Medicines...